The speeches (s-peach-es?) just finished this morning at the Ontario Premier’s breakfast.
Minister of Research and Innovation John Wilkinson announced that Ontario has recently completed 2 new BIP investments:
- a Pfizer collaboration with the Ontario Institute for Cancer Research (OICR); and
- GSK Canada for manufacturing in Mississauga.
Ontario’s Premier — Dalton McGuinty, winner of BIO’s second annual International Leadership Award — spoke next, highlighting the Ontario Innovation Agenda, including BIP, business tax reductions and recent funding in the Emerging Technologies Fund and the new $100 million for genomics research.
Dr. Nagy also spoke, emphasizing the $100 million of new funding and the value of a peer group of 95 P.I.’s in Ontario working on stem cells and regenerative medicine. Current work focuses on cell type switching without regression to pluripotency.
On to the omelet…
P.S. First time here at the Cross-Border Biotech Blog? Welcome! Check out who we are, check out our Trends in 2009 series, or hit the search and navigation tools on your right and see if you see anything interesting.
